サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1769907

医薬品有効成分（API）の世界市場：産業分析、市場規模・シェア・成長・動向・予測 (2025年～2035年)

Active Pharmaceutical Ingredients Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日
ページ情報
英文 242 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
医薬品有効成分（API）の世界市場：産業分析、市場規模・シェア・成長・動向・予測 (2025年～2035年)
出版日: 2025年05月30日
発行: Transparency Market Research
ページ情報: 英文 242 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医薬品有効成分（API）市場 - 分析範囲

TMRの調査レポート「世界の医薬品有効成分（API）市場」は、2025年から2035年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2025年を基準年、2035年を予測年として、2019年から2035年までの世界の医薬品有効成分（API）市場の収益と予測を提供します。また、2025年から2035年までの世界の医薬品有効成分（API）市場の複合年間成長率（CAGR、%）も掲載しています。

当レポートは広範な調査を経て作成されています。一次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、医薬品有効成分（API）市場を推察しました。

市場概況
市場規模（2024年） 2,509億米ドル
市場規模（2035年） 4,669億米ドル
CAGR 5.8%

当レポートでは、世界の医薬品有効成分（API）市場の競合情勢について分析しています。世界の医薬品有効成分（API）市場で事業を展開する主要企業が特定され、各企業がさまざまな属性でプロファイルされています。企業概要・財務状況・最新動向・SWOTが、当レポートで紹介されている世界の医薬品有効成分（API）市場における各企業の属性です。

目次

第1章 序論

第2章 前提条件と分析手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の医薬品有効成分（API）市場分析と予測（2020～2035年）

第5章 主要洞察

  • 主要国の医療支出データ
  • サプライチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • 主要地域/国における規制状況
  • 主要地域/国における新規市場参入企業向けの市場開拓戦略
  • 価格分析
  • 主要な業界イベント
  • ディストリビューターの情勢
  • サプライチェーン分析

第6章 世界の市場分析と予測：分子の種類別

  • イントロダクション・定義
  • 主な分析結果/進展
  • 市場予測（金額ベース）：分子の種類別（2020～2035年）
    • アセトアミノフェン
    • ナプロキセン
    • フロセミド
    • ニトロフラントイン
    • スルファドキシン
    • ピリメタミン
    • アモジアキン
    • アタザナビル硫酸塩
    • ニメスリド
    • シプロフロキサシン
    • スルファドキシン
    • ピペラキンリン酸
    • ソタロール
    • レベチラセタム
    • ジクロフェナク
    • アジスロマイシン
    • その他
  • 市場の魅力：分子の種類別

第7章 世界市場の分析と予測：生産の種類別

  • イントロダクション・定義
  • 主な分析結果/進展
  • 市場予測（金額ベース）：生産の種類別（2020～2035年）
    • 自社生産/社内
    • 外注
  • 市場の魅力：生産の種類別

第8章 世界市場の分析と予測：製品種類別

  • イントロダクション・定義
  • 主な分析結果/進展
  • 市場予測（金額ベース）：製品種類別（2020～2035年）
    • 低効力API
    • 高効力API
  • 市場の魅力：製品種類別

第9章 世界市場の分析と予測：APIの種類別

  • イントロダクション・定義
  • 主な分析結果/進展
  • 市場予測（金額ベース）：APIの種類別（2020～2035年）
    • 合成
    • 天然
  • 市場の魅力：APIの種類別

第10章 世界市場の分析と予測：スケール別

  • イントロダクション・定義
  • 主な分析結果/進展
  • 市場予測（金額ベース）：スケール別（2020～2035年）
    • パイロット
    • 大規模
  • 市場の魅力：スケール別

第11章 世界の市場分析と予測：用途別

  • イントロダクション・定義
  • 主な分析結果/進展
  • 市場予測（金額ベース）：用途別（2020～2035年）
    • 商業用
    • 研究
  • 市場の魅力：用途別

第12章 世界市場の分析と予測：エンドユーザー別

  • イントロダクション・定義
  • 主な分析結果/進展
  • 市場予測（金額ベース）：エンドユーザー別（2020～2035年）
    • 製薬会社
    • バイオテクノロジー企業
    • CMO（医薬品開発業務受託機関）
    • その他
  • 市場の魅力：エンドユーザー別

第13章 世界市場の分析と予測：地域別

  • 主な分析結果
  • 市場予測（金額ベース）：地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第14章 北米市場の分析と予測

  • 米国
  • カナダ

第15章 欧州市場の分析と予測

  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • スイス
  • オランダ
  • その他欧州

第16章 アジア太平洋市場の分析と予測

  • 中国
  • 日本
  • インド
  • オーストラリアとニュージーランド
  • 韓国
  • その他アジア太平洋

第17章 ラテンアメリカ市場の分析と予測

  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ

第18章 中東・アフリカ市場の分析と予測

  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第19章 競合情勢

  • 市場企業・競合マトリックス（企業の階層別・規模別）
  • 市場シェア分析：企業別（2024年）
  • 企業プロファイル
    • Merck KGaA
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc
    • Mangalam Drugs & Organics Limited
    • Viatris Inc.
    • Lonza.
    • Piramal Pharma Solutions
    • HISUN USA, inc.
    • Ipca Laboratories Ltd
    • AbbVie Inc.
    • Alembic Pharmaceuticals Limited
    • Biocon
    • Boehringer Ingelheim
    • Cambrex Corporation.
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Cipla.
図表

List of Tables

  • Table 01: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Molecule Type, 2020 to 2035
  • Table 02: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Production Type, 2020 to 2035
  • Table 03: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Product Type, 2020 to 2035
  • Table 04: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by API Type, 2020 to 2035
  • Table 05: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Scale, 2020 to 2035
  • Table 06: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Application 2020 to 2035
  • Table 07: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by End-user, 2020 to 2035
  • Table 08: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
  • Table 09: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
  • Table 10: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Molecule Type, 2020 to 2035
  • Table 11: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Production Type, 2020 to 2035
  • Table 12: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Product Type, 2020 to 2035
  • Table 13: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by API Type, 2020 to 2035
  • Table 14: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Scale, 2020 to 2035
  • Table 15: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Application 2020 to 2035
  • Table 16: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by End-user, 2020 to 2035
  • Table 17: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
  • Table 18: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Molecule Type, 2020 to 2035
  • Table 19: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Production Type, 2020 to 2035
  • Table 20: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Product Type, 2020 to 2035
  • Table 21: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by API Type, 2020 to 2035
  • Table 22: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Scale, 2020 to 2035
  • Table 23: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Application 2020 to 2035
  • Table 24: Europe - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by End-user, 2020 to 2035
  • Table 25: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
  • Table 26: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Molecule Type, 2020 to 2035
  • Table 27: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Production Type, 2020 to 2035
  • Table 28: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Product Type, 2020 to 2035
  • Table 29: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by API Type, 2020 to 2035
  • Table 30: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Scale, 2020 to 2035
  • Table 31: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Application 2020 to 2035
  • Table 32: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by End-user, 2020 to 2035
  • Table 33: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
  • Table 34: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Molecule Type, 2020 to 2035
  • Table 35: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Production Type, 2020 to 2035
  • Table 36: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Product Type, 2020 to 2035
  • Table 37: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by API Type, 2020 to 2035
  • Table 38: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Scale, 2020 to 2035
  • Table 39: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Application 2020 to 2035
  • Table 40: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by End-user, 2020 to 2035
  • Table 41: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
  • Table 42: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Molecule Type, 2020 to 2035
  • Table 43: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Production Type, 2020 to 2035
  • Table 44: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Product Type, 2020 to 2035
  • Table 45: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by API Type, 2020 to 2035
  • Table 46: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Scale, 2020 to 2035
  • Table 47: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by Application 2020 to 2035
  • Table 48: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Bn) Forecast, by End-user, 2020 to 2035

List of Figures

  • Figure 01: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Molecule Type, 2024 and 2035
  • Figure 02: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Molecule Type, 2025 to 2035
  • Figure 03: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Acetaminophen, 2020 to 2035
  • Figure 04: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Naproxen, 2020 to 2035
  • Figure 05: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Furosemide, 2020 to 2035
  • Figure 06: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Nitrofurantoin, 2020 to 2035
  • Figure 07: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Acetaminophen, 2020 to 2035
  • Figure 08: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Sulfadoxine, 2020 to 2035
  • Figure 09: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Pyrimethamine, 2020 to 2035
  • Figure 10: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Amodiaquine, 2020 to 2035
  • Figure 11: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Atazanavir Sulfate, 2020 to 2035
  • Figure 12: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Nimesulide, 2020 to 2035
  • Figure 13: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Ciprofloxacin, 2020 to 2035
  • Figure 14: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Sulfadoxine, 2020 to 2035
  • Figure 15: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Piperaquine Phosphate Sotalol, 2020 to 2035
  • Figure 16: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Levetiracetam, 2020 to 2035
  • Figure 17: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Diclofenac, 2020 to 2035
  • Figure 18: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Azithromycin, 2020 to 2035
  • Figure 19: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Others, 2020 to 2035
  • Figure 20: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Production Type, 2024 and 2035
  • Figure 21: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Production Type, 2025 to 2035
  • Figure 22: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Captive/In House, 2020 to 2035
  • Figure 23: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Outsourcing, 2020 to 2035
  • Figure 24: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Product Type, 2024 and 2035
  • Figure 25: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Product Type, 2025 to 2035
  • Figure 26: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Low Potent API, 2020 to 2035
  • Figure 27: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by High Potent API, 2020 to 2035
  • Figure 28: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By API Type, 2024 and 2035
  • Figure 29: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By API Type, 2025 to 2035
  • Figure 30: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Synthetic, 2020 to 2035
  • Figure 31: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Natural, 2020 to 2035
  • Figure 32: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Scale, 2024 and 2035
  • Figure 33: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Scale, 2025 to 2035
  • Figure 34: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Pilot, 2020 to 2035
  • Figure 35: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Large, 2020 to 2035
  • Figure 36: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 37: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 38: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Commercial, 2020 to 2035
  • Figure 39: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Research, 2020 to 2035
  • Figure 40: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 41: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 42: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Pharmaceutical Companies, 2020 to 2035
  • Figure 43: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Biotechnological Companies, 2020 to 2035
  • Figure 44: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Contract Manufacturing Organization's (CMOs), 2020 to 2035
  • Figure 45: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn), by Others, 2020 to 2035
  • Figure 46: Global Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 47: Global Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Region, 2025 to 2035
  • Figure 48: North America - Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 49: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 50: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Country, 2025 to 2035
  • Figure 51: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Molecule Type, 2024 and 2035
  • Figure 52: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Molecule Type, 2025 to 2035
  • Figure 53: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Production Type, 2024 and 2035
  • Figure 54: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Production Type, 2025 to 2035
  • Figure 55: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Product Type, 2024 and 2035
  • Figure 56: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Product Type, 2025 to 2035
  • Figure 57: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By API Type, 2024 and 2035
  • Figure 58: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By API Type, 2025 to 2035
  • Figure 59: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Scale, 2024 and 2035
  • Figure 60: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Scale, 2025 to 2035
  • Figure 61: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 62: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 63: North America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 64: North America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 65: Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 66: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 67: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
  • Figure 68: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Molecule Type, 2024 and 2035
  • Figure 69: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Molecule Type, 2025 to 2035
  • Figure 70: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Production Type, 2024 and 2035
  • Figure 71: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Production Type, 2025 to 2035
  • Figure 72: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Product Type, 2024 and 2035
  • Figure 73: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Product Type, 2025 to 2035
  • Figure 74: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By API Type, 2024 and 2035
  • Figure 75: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By API Type, 2025 to 2035
  • Figure 76: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Scale, 2024 and 2035
  • Figure 77: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Scale, 2025 to 2035
  • Figure 78: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 79: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 80: Europe - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 81: Europe - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 82: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 83: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 84: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
  • Figure 85: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Molecule Type, 2024 and 2035
  • Figure 86: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Molecule Type, 2025 to 2035
  • Figure 87: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Production Type, 2024 and 2035
  • Figure 88: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Production Type, 2025 to 2035
  • Figure 89: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Product Type, 2024 and 2035
  • Figure 90: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Product Type, 2025 to 2035
  • Figure 91: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By API Type, 2024 and 2035
  • Figure 92: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By API Type, 2025 to 2035
  • Figure 93: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Scale, 2024 and 2035
  • Figure 94: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Scale, 2025 to 2035
  • Figure 95: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 96: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 97: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 98: Asia Pacific - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 99: Latin America - Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 100: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 101: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
  • Figure 102: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Molecule Type, 2024 and 2035
  • Figure 103: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Molecule Type, 2025 to 2035
  • Figure 104: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Production Type, 2024 and 2035
  • Figure 105: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Production Type, 2025 to 2035
  • Figure 106: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Product Type, 2024 and 2035
  • Figure 107: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Product Type, 2025 to 2035
  • Figure 108: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By API Type, 2024 and 2035
  • Figure 109: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By API Type, 2025 to 2035
  • Figure 110: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Scale, 2024 and 2035
  • Figure 111: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Scale, 2025 to 2035
  • Figure 112: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 113: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 114: Latin America - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 115: Latin America - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 116: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 117: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 118: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
  • Figure 119: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, by Molecule Type, 2024 and 2035
  • Figure 120: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, by Molecule Type, 2025 to 2035
  • Figure 121: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Production Type, 2024 and 2035
  • Figure 122: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Production Type, 2025 to 2035
  • Figure 123: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Product Type, 2024 and 2035
  • Figure 124: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Product Type, 2025 to 2035
  • Figure 125: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By API Type, 2024 and 2035
  • Figure 126: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By API Type, 2025 to 2035
  • Figure 127: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Scale, 2024 and 2035
  • Figure 128: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Scale, 2025 to 2035
  • Figure 129: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 130: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 131: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 132: Middle East & Africa - Active Pharmaceutical Ingredients (API) Market Attractiveness Analysis, By End-user, 2025 to 2035
目次
Product Code: TMRGL1690

Active Pharmaceutical Ingredients (API) Market - Scope of Report

TMR's report on the global active pharmaceutical ingredients (API) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global active pharmaceutical ingredients (API) market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global active pharmaceutical ingredients (API) market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the active pharmaceutical ingredients (API) market.

Market Snapshot
Market Value in 2024US$ 250.9 Bn
Market Value in 2035US$ 466.9 Bn
CAGR5.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global active pharmaceutical ingredients (API) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global active pharmaceutical ingredients (API) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global active pharmaceutical ingredients (API) market.

The report delves into the competitive landscape of the global active pharmaceutical ingredients (API) market. Key players operating in the global active pharmaceutical ingredients (API) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global active pharmaceutical ingredients (API) market profiled in this report.

Key Questions Answered in Global active pharmaceutical ingredients (API) Market Report:

  • What is the sales/revenue generated by active pharmaceutical ingredients (API) across all regions during the forecast period?
  • What are the opportunities in the global active pharmaceutical ingredients (API) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Active Pharmaceutical Ingredients (API) Market - Research Objectives and Research Approach

The comprehensive report on the global active pharmaceutical ingredients (API) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global active pharmaceutical ingredients (API) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global active pharmaceutical ingredients (API) market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Active Pharmaceutical Ingredients (API) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, 2020 to 2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Healthcare Expenditure Data across Key Countries
  • 5.2. Supply Chain Analysis
  • 5.3. PESTLE Analysis
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. Regulatory Landscape across Key Regions / Countries
  • 5.6. Go-to-Market Strategy for New Market Entrants across Key Regions / Countries
  • 5.7. Pricing Analysis
  • 5.8. Key Industry Events
  • 5.9. Distributors Landscape
  • 5.10. Supply Chain Analysis

6. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Molecule Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
    • 6.3.1. Acetaminophen
    • 6.3.2. Naproxen
    • 6.3.3. Furosemide
    • 6.3.4. Nitrofurantoin
    • 6.3.5. Sulfadoxine
    • 6.3.6. Pyrimethamine
    • 6.3.7. Amodiaquine
    • 6.3.8. Atazanavir Sulfate
    • 6.3.9. Nimesulide
    • 6.3.10. Ciprofloxacin
    • 6.3.11. Sulfadoxine
    • 6.3.12. Piperaquine Phosphate
    • 6.3.13. Sotalol
    • 6.3.14. Levetiracetam
    • 6.3.15. Diclofenac
    • 6.3.16. Azithromycin
    • 6.3.17. Others
  • 6.4. Market Attractiveness By Molecule Type

7. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Production Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Production Type, 2020 to 2035
    • 7.3.1. Captive/In House
    • 7.3.2. Outsourcing
  • 7.4. Market Attractiveness By Production Type

8. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Product Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Product Type, 2020 to 2035
    • 8.3.1. Low Potent API
    • 8.3.2. High Potent API
  • 8.4. Market Attractiveness By Product Type

9. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By API Type

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By API Type, 2020 to 2035
    • 9.3.1. Synthetic
    • 9.3.2. Natural
  • 9.4. Market Attractiveness By API Type

10. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Scale

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast By Scale, 2020 to 2035
    • 10.3.1. Pilot
    • 10.3.2. Large
  • 10.4. Market Attractiveness By Scale

11. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Application

  • 11.1. Introduction & Definition
  • 11.2. Key Findings / Developments
  • 11.3. Market Value Forecast By Application, 2020 to 2035
    • 11.3.1. Commercial
    • 11.3.2. Research
  • 11.4. Market Attractiveness By Application

12. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By End-user

  • 12.1. Introduction & Definition
  • 12.2. Key Findings / Developments
  • 12.3. Market Value Forecast By Application, 2020 to 2035
    • 12.3.1. Pharmaceutical Companies
    • 12.3.2. Biotechnological Companies
    • 12.3.3. Contract Manufacturing Organisation's (CMO's)
    • 12.3.4. Others
  • 12.4. Market Attractiveness By End User

13. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Region

  • 13.1. Key Findings
  • 13.2. Market Value Forecast By Region
    • 13.2.1. North America
    • 13.2.2. Europe
    • 13.2.3. Asia Pacific
    • 13.2.4. Latin America
    • 13.2.5. Middle East & Africa
  • 13.3. Market Attractiveness By Region

14. North America Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
    • 14.2.1. Acetaminophen
    • 14.2.2. Naproxen
    • 14.2.3. Furosemide
    • 14.2.4. Nitrofurantoin
    • 14.2.5. Sulfadoxine
    • 14.2.6. Pyrimethamine
    • 14.2.7. Amodiaquine
    • 14.2.8. Atazanavir Sulfate
    • 14.2.9. Nimesulide
    • 14.2.10. Ciprofloxacin
    • 14.2.11. Sulfadoxine
    • 14.2.12. Piperaquine Phosphate
    • 14.2.13. Sotalol
    • 14.2.14. Levetiracetam
    • 14.2.15. Diclofenac
    • 14.2.16. Azithromycin
    • 14.2.17. Others
  • 14.3. Market Value Forecast By Production Type, 2020 to 2035
    • 14.3.1. Captive/In House
    • 14.3.2. Outsourcing
  • 14.4. Market Value Forecast By Product Type, 2020 to 2035
    • 14.4.1. Low Potent API
    • 14.4.2. High Potent API
  • 14.5. Market Value Forecast By API Type, 2020 to 2035
    • 14.5.1. Synthetic
    • 14.5.2. Natural
  • 14.6. Market Value Forecast By Scale, 2020 to 2035
    • 14.6.1. Pilot
    • 14.6.2. Large
  • 14.7. Market Value Forecast By Application, 2020 to 2035
    • 14.7.1. Commercial
    • 14.7.2. Research
  • 14.8. Market Value Forecast By End-user, 2020 to 2035
    • 14.8.1. Pharmaceutical Companies
    • 14.8.2. Biotechnological Companies
    • 14.8.3. Contract Manufacturing Organization's (CMO)
    • 14.8.4. Others
  • 14.9. Market Value Forecast By Country, 2020 to 2035
    • 14.9.1. U.S.
    • 14.9.2. Canada
  • 14.10. Market Attractiveness Analysis
    • 14.10.1. By Molecule Type
    • 14.10.2. By Production Type
    • 14.10.3. By Product Type
    • 14.10.4. By API Type
    • 14.10.5. By Scale
    • 14.10.6. By Application
    • 14.10.7. By End-user
    • 14.10.8. By Country

15. Europe Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
    • 15.2.1. Acetaminophen
    • 15.2.2. Naproxen
    • 15.2.3. Furosemide
    • 15.2.4. Nitrofurantoin
    • 15.2.5. Sulfadoxine
    • 15.2.6. Pyrimethamine
    • 15.2.7. Amodiaquine
    • 15.2.8. Atazanavir Sulfate
    • 15.2.9. Nimesulide
    • 15.2.10. Ciprofloxacin
    • 15.2.11. Sulfadoxine
    • 15.2.12. Piperaquine Phosphate
    • 15.2.13. Sotalol
    • 15.2.14. Levetiracetam
    • 15.2.15. Diclofenac
    • 15.2.16. Azithromycin
    • 15.2.17. Others
  • 15.3. Market Value Forecast By Production Type, 2020 to 2035
    • 15.3.1. Captive/In House
    • 15.3.2. Outsourcing
  • 15.4. Market Value Forecast By Product Type, 2020 to 2035
    • 15.4.1. Low Potent API
    • 15.4.2. High Potent API
  • 15.5. Market Value Forecast By API Type, 2020 to 2035
    • 15.5.1. Synthetic
    • 15.5.2. Natural
  • 15.6. Market Value Forecast By Scale, 2020 to 2035
    • 15.6.1. Pilot
    • 15.6.2. Large
  • 15.7. Market Value Forecast By Application, 2020 to 2035
    • 15.7.1. Commercial
    • 15.7.2. Research
  • 15.8. Market Value Forecast By End-user, 2020 to 2035
    • 15.8.1. Pharmaceutical Companies
    • 15.8.2. Biotechnological Companies
    • 15.8.3. Contract Manufacturing Organization's (CMO)
    • 15.8.4. Others
  • 15.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
    • 15.9.1. Germany
    • 15.9.2. U.K.
    • 15.9.3. France
    • 15.9.4. Spain
    • 15.9.5. Italy
    • 15.9.6. Switzerland
    • 15.9.7. The Netherlands
    • 15.9.8. Rest of Europe
  • 15.10. Market Attractiveness Analysis
    • 15.10.1. By Molecule Type
    • 15.10.2. By Production Type
    • 15.10.3. By Product Type
    • 15.10.4. By API Type
    • 15.10.5. By Scale
    • 15.10.6. By Application
    • 15.10.7. By End-user
    • 15.10.8. By Country/Sub-region

16. Asia Pacific Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
    • 16.2.1. Acetaminophen
    • 16.2.2. Naproxen
    • 16.2.3. Furosemide
    • 16.2.4. Nitrofurantoin
    • 16.2.5. Sulfadoxine
    • 16.2.6. Pyrimethamine
    • 16.2.7. Amodiaquine
    • 16.2.8. Atazanavir Sulfate
    • 16.2.9. Nimesulide
    • 16.2.10. Ciprofloxacin
    • 16.2.11. Sulfadoxine
    • 16.2.12. Piperaquine Phosphate
    • 16.2.13. Sotalol
    • 16.2.14. Levetiracetam
    • 16.2.15. Diclofenac
    • 16.2.16. Azithromycin
    • 16.2.17. Others
  • 16.3. Market Value Forecast By Production Type, 2020 to 2035
    • 16.3.1. Captive/In House
    • 16.3.2. Outsourcing
  • 16.4. Market Value Forecast By Product Type, 2020 to 2035
    • 16.4.1. Low Potent API
    • 16.4.2. High Potent API
  • 16.5. Market Value Forecast By API Type, 2020 to 2035
    • 16.5.1. Synthetic
    • 16.5.2. Natural
  • 16.6. Market Value Forecast By Scale, 2020 to 2035
    • 16.6.1. Pilot
    • 16.6.2. Large
  • 16.7. Market Value Forecast By Application, 2020 to 2035
    • 16.7.1. Commercial
    • 16.7.2. Research
  • 16.8. Market Value Forecast By End-user, 2020 to 2035
    • 16.8.1. Pharmaceutical Companies
    • 16.8.2. Biotechnological Companies
    • 16.8.3. Contract Manufacturing Organization's (CMO)
    • 16.8.4. Others
  • 16.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
    • 16.9.1. China
    • 16.9.2. Japan
    • 16.9.3. India
    • 16.9.4. Australia & New Zealand
    • 16.9.5. South Korea
    • 16.9.6. Rest of Asia Pacific
  • 16.10. Market Attractiveness Analysis
    • 16.10.1. By Molecule Type
    • 16.10.2. By Production Type
    • 16.10.3. By Product Type
    • 16.10.4. By API Type
    • 16.10.5. By Scale
    • 16.10.6. By Application
    • 16.10.7. By End-user
    • 16.10.8. By Country/Sub-region

17. Latin America Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
    • 17.2.1. Acetaminophen
    • 17.2.2. Naproxen
    • 17.2.3. Furosemide
    • 17.2.4. Nitrofurantoin
    • 17.2.5. Sulfadoxine
    • 17.2.6. Pyrimethamine
    • 17.2.7. Amodiaquine
    • 17.2.8. Atazanavir Sulfate
    • 17.2.9. Nimesulide
    • 17.2.10. Ciprofloxacin
    • 17.2.11. Sulfadoxine
    • 17.2.12. Piperaquine Phosphate
    • 17.2.13. Sotalol
    • 17.2.14. Levetiracetam
    • 17.2.15. Diclofenac
    • 17.2.16. Azithromycin
    • 17.2.17. Others
  • 17.3. Market Value Forecast By Production Type, 2020 to 2035
    • 17.3.1. Captive/In House
    • 17.3.2. Outsourcing
  • 17.4. Market Value Forecast By Product Type, 2020 to 2035
    • 17.4.1. Low Potent API
    • 17.4.2. High Potent API
  • 17.5. Market Value Forecast By API Type, 2020 to 2035
    • 17.5.1. Synthetic
    • 17.5.2. Natural
  • 17.6. Market Value Forecast By Scale, 2020 to 2035
    • 17.6.1. Pilot
    • 17.6.2. Large
  • 17.7. Market Value Forecast By Application, 2020 to 2035
    • 17.7.1. Commercial
    • 17.7.2. Research
  • 17.8. Market Value Forecast By End-user, 2020 to 2035
    • 17.8.1. Pharmaceutical Companies
    • 17.8.2. Biotechnological Companies
    • 17.8.3. Contract Manufacturing Organization's (CMO)
    • 17.8.4. Others
  • 17.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
    • 17.9.1. Brazil
    • 17.9.2. Mexico
    • 17.9.3. Argentina
    • 17.9.4. Rest of Latin America
  • 17.10. Market Attractiveness Analysis
    • 17.10.1. By Molecule Type
    • 17.10.2. By Production Type
    • 17.10.3. By Product Type
    • 17.10.4. By API Type
    • 17.10.5. By Scale
    • 17.10.6. By Application
    • 17.10.7. By Application
    • 17.10.8. By Country/Sub-region

18. Middle East & Africa Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

  • 18.1. Introduction
    • 18.1.1. Key Findings
  • 18.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
    • 18.2.1. Acetaminophen
    • 18.2.2. Naproxen
    • 18.2.3. Furosemide
    • 18.2.4. Nitrofurantoin
    • 18.2.5. Sulfadoxine
    • 18.2.6. Pyrimethamine
    • 18.2.7. Amodiaquine
    • 18.2.8. Atazanavir Sulfate
    • 18.2.9. Nimesulide
    • 18.2.10. Ciprofloxacin
    • 18.2.11. Sulfadoxine
    • 18.2.12. Piperaquine Phosphate
    • 18.2.13. Sotalol
    • 18.2.14. Levetiracetam
    • 18.2.15. Diclofenac
    • 18.2.16. Azithromycin
    • 18.2.17. Others
  • 18.3. Market Value Forecast By Production Type, 2020 to 2035
    • 18.3.1. Captive/In House
    • 18.3.2. Outsourcing
  • 18.4. Market Value Forecast By Product Type, 2020 to 2035
    • 18.4.1. Low Potent API
    • 18.4.2. High Potent API
  • 18.5. Market Value Forecast By API Type, 2020 to 2035
    • 18.5.1. Synthetic
    • 18.5.2. Natural
  • 18.6. Market Value Forecast By Scale, 2020 to 2035
    • 18.6.1. Pilot
    • 18.6.2. Large
  • 18.7. Market Value Forecast By Application, 2020 to 2035
    • 18.7.1. Commercial
    • 18.7.2. Research
  • 18.8. Market Value Forecast By End-user, 2020 to 2035
    • 18.8.1. Pharmaceutical Companies
    • 18.8.2. Biotechnological Companies
    • 18.8.3. Contract Manufacturing Organization's (CMO)
    • 18.8.4. Others
  • 18.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
    • 18.9.1. GCC Countries
    • 18.9.2. South Africa
    • 18.9.3. Rest of Middle East & Africa
  • 18.10. Market Attractiveness Analysis
    • 18.10.1. By Molecule Type
    • 18.10.2. By Production Type
    • 18.10.3. By Product Type
    • 18.10.4. By API Type
    • 18.10.5. By Scale
    • 18.10.6. By Application
    • 18.10.7. By End-user
    • 18.10.8. By Country/Sub-region

19. Competition Landscape

  • 19.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 19.2. Market Share Analysis By Company (2024)
  • 19.3. Company Profiles
    • 19.3.1. Merck KGaA
      • 19.3.1.1. Company Overview
      • 19.3.1.2. Financial Overview
      • 19.3.1.3. Product Portfolio
      • 19.3.1.4. Business Strategies
      • 19.3.1.5. Recent Developments
    • 19.3.2. Teva Pharmaceutical Industries Ltd.
      • 19.3.2.1. Company Overview
      • 19.3.2.2. Financial Overview
      • 19.3.2.3. Product Portfolio
      • 19.3.2.4. Business Strategies
      • 19.3.2.5. Recent Developments
    • 19.3.3. Pfizer Inc
      • 19.3.3.1. Company Overview
      • 19.3.3.2. Financial Overview
      • 19.3.3.3. Product Portfolio
      • 19.3.3.4. Business Strategies
      • 19.3.3.5. Recent Developments
    • 19.3.4. Mangalam Drugs & Organics Limited
      • 19.3.4.1. Company Overview
      • 19.3.4.2. Financial Overview
      • 19.3.4.3. Product Portfolio
      • 19.3.4.4. Business Strategies
      • 19.3.4.5. Recent Developments
    • 19.3.5. Viatris Inc.
      • 19.3.5.1. Company Overview
      • 19.3.5.2. Financial Overview
      • 19.3.5.3. Product Portfolio
      • 19.3.5.4. Business Strategies
      • 19.3.5.5. Recent Developments
    • 19.3.6. Lonza.
      • 19.3.6.1. Company Overview
      • 19.3.6.2. Financial Overview
      • 19.3.6.3. Product Portfolio
      • 19.3.6.4. Business Strategies
      • 19.3.6.5. Recent Developments
    • 19.3.7. Piramal Pharma Solutions
      • 19.3.7.1. Company Overview
      • 19.3.7.2. Financial Overview
      • 19.3.7.3. Product Portfolio
      • 19.3.7.4. Business Strategies
      • 19.3.7.5. Recent Developments
    • 19.3.8. HISUN USA, inc.
      • 19.3.8.1. Company Overview
      • 19.3.8.2. Financial Overview
      • 19.3.8.3. Product Portfolio
      • 19.3.8.4. Business Strategies
      • 19.3.8.5. Recent Developments
    • 19.3.9. Ipca Laboratories Ltd
      • 19.3.9.1. Company Overview
      • 19.3.9.2. Financial Overview
      • 19.3.9.3. Product Portfolio
      • 19.3.9.4. Business Strategies
      • 19.3.9.5. Recent Developments
    • 19.3.10. AbbVie Inc.
      • 19.3.10.1. Company Overview
      • 19.3.10.2. Financial Overview
      • 19.3.10.3. Product Portfolio
      • 19.3.10.4. Business Strategies
      • 19.3.10.5. Recent Developments
    • 19.3.11. Alembic Pharmaceuticals Limited
      • 19.3.11.1. Company Overview
      • 19.3.11.2. Financial Overview
      • 19.3.11.3. Product Portfolio
      • 19.3.11.4. Business Strategies
      • 19.3.11.5. Recent Developments
    • 19.3.12. Biocon
      • 19.3.12.1. Company Overview
      • 19.3.12.2. Financial Overview
      • 19.3.12.3. Product Portfolio
      • 19.3.12.4. Business Strategies
      • 19.3.12.5. Recent Developments
    • 19.3.13. Boehringer Ingelheim
      • 19.3.13.1. Company Overview
      • 19.3.13.2. Financial Overview
      • 19.3.13.3. Product Portfolio
      • 19.3.13.4. Business Strategies
      • 19.3.13.5. Recent Developments
    • 19.3.14. Cambrex Corporation.
      • 19.3.14.1. Company Overview
      • 19.3.14.2. Financial Overview
      • 19.3.14.3. Product Portfolio
      • 19.3.14.4. Business Strategies
      • 19.3.14.5. Recent Developments
    • 19.3.15. Dr. Reddy's Laboratories Ltd.
      • 19.3.15.1. Company Overview
      • 19.3.15.2. Financial Overview
      • 19.3.15.3. Product Portfolio
      • 19.3.15.4. Business Strategies
      • 19.3.15.5. Recent Developments
    • 19.3.16. Sun Pharmaceutical Industries Ltd.
      • 19.3.16.1. Company Overview
      • 19.3.16.2. Financial Overview
      • 19.3.16.3. Product Portfolio
      • 19.3.16.4. Business Strategies
      • 19.3.16.5. Recent Developments
    • 19.3.17. Cipla.
      • 19.3.17.1. Company Overview
      • 19.3.17.2. Financial Overview
      • 19.3.17.3. Product Portfolio
      • 19.3.17.4. Business Strategies
      • 19.3.17.5. Recent Developments